KRAS and neoplasm: Several case reports revealed possible intrinsic factors of primary resistance to crizotinib, including MYC amplification [195], ALK/KRAS co-alteration [196, 197], Bim deletion polymorphism [198], high tumor mutational burden (TMB), and mutations in DNA repair genes (including TP53 G245S) [199].